November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at firstname.lastname@example.org)
December 11, 2013
Twenty injured in nighttime clashes in Kyiv's Independence Square hospitalized
Lavrov - necessary to launch consultations on parameters of final agreement on Iran's nuclear problem
Prokhorov suggests uniting Russia, Europe and Japan as economic platform to compete with U.S. and China
EU sees its role in organizing dialog between conflict parties in Ukraine - Ashton
Irkutsk govt, Interfax will work together to cut non-payment
Yanukovych invites reps of all political forces, clergy to have dialog
Business ombudsman Titov expected wider economic amnesty in Russia
YANUKOVYCH URGES OPPOSITION NOT TO REFUSE PARTICIPATING IN NATION-WIDE DIALOG
There are 2-3 candidates running for every seat in Turkmen parliament
Main indexes of the Russia stock market for December 11
Results of Interregional Trading for OFZ & OBR
Belarus announces tender to sell state stake in MTS; starting price: $863 mln (Part 2)
Dollar, euro slightly higher against ruble on Wednesday